December #54 : Less Is More - by Lark Lands

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

The AIDS Decade: The 99 Greatest Moments of the '90s

Inside Agitator

Happy Holidays?

It's 10 O'Clock. Do You Know Where Your Meds Are?

Publisher's Letter

Mailbox-December 1999

Your Money or Your Life

Mass Appeal

STARHS Search

Parallel Universe

Arts

Syph 'N' Spin

Hot Copy

Attention, Shoppers

Where Did HIV Come From?

The Spirit of St. Louis

Splendor in the Pines

Keeping the Faith

Milestones

Tenement Dreams

10,000 Hemophiliacs

Just Eat It

Food Fight

The Hit List

Compound Interest

When to Treat Hep C?

Hep Help Hurray!

The Scoop on Poop

Could You Have HAD?

Shelf Life

Vintage Gallo

Days of Wine and Doses

Less Is More

Cutting Corners

A Day Without

Catching Up With



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

December 1999

Less Is More

by Lark Lands

Researchers from the University of Maryland’s Institute of Human Virology may have found a way to make one of the newest antiretrovirals even more effective. Abacavir (Ziagen), Glaxo Wellcome’s new nuke, works as a defective mimic of guanosine, a building block of all cells’ genetic material, that HIV needs for replication. David Oldach, MD, and David Margolis, MD, hit upon mixing abacavir with mycophenolic acid, a drug used in transplant patients to help prevent organ rejection by depleting the guanosine in white blood cells. The scientists reasoned that if the transplant drug made fewer real guanosine building blocks available to HIV for replication, then it could help abacavir’s fakes boost the odds against the virus. In fact, the combo made abacavir six times better at blocking HIV, which raises the possibility of using lower, less toxic doses of the drug. “You’d be hard-pressed to find another combination of anti-HIV drugs with this profound an effect,” Margolis says. Remarkably, this experimental treatment went from first thought to human trials in a mere six months.



[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    adorableone
    New York
    New York


    RyGuy00
    New York
    New York


    youngbloodlatino
    Columbia
    Maryland


    RayOctober
    Richmond
    Virginia
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.